CTT Pharma

CTT Pharma is a development-stage biotechnology company with a mission to improve patient quality of life through its innovative micelle-encapsulated oral thin-film delivery platform. Key achievements include a robust global patent portfolio, a completed PCAOB audit enabling an OTCQB uplist, and a pending NIH grant proposal with Johns Hopkins University for a smoking cessation clinical trial. The company's near-term strategy focuses on capital-efficient progression towards manufacturing and SEC reporting status in 2025/2026, initially targeting the nutraceutical and nicotine replacement therapy markets as regulatory and commercial pathways are established.

Proprietary micelle encapsulation technology embedded in fast-dissolving oral thin films, designed to enhance bioavailability, enable rapid onset, and improve taste masking for a wide range of active compounds.

CTT competes in oral thin films against established players like Aquestive Therapeutics and IntelGenx, and in nicotine replacement against giants like Johnson & Johnson. Its primary competitive moat is its international patent portfolio for micelle encapsulation, but it lacks the resources and commercial infrastructure of its peers, making partnerships critical.